Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

CancerGen > Monitoring Disease > Flashcards

Monitoring Disease Flashcards

1
Q

What is the name of the criteria created for monitoring disease to know in a standardised way how to monitor someone and when to offer certain drugs, first done in 2000, then redone in 2009?

A

RECIST Criteria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

For patient eligibility for the RECIST criteria, what needs to have been done?

A

Have at least one lesion accurately assessed by CT or MRI scan at the baseline, and then follow up visits too

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What areas of the anatomy require coverage when monitoring?

A

All known areas with a predilection for metastasis. Normally chest, pelvis, abdomen. Plus any additional areas of concern

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the 3 types of lesion to be monitored?

A

The target lesions. Non-target lesions, and any new lesions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Target lesions and Non-target lesions should ideally be measured by CT. If not, what other methods?

A

MRI, X-ray, clinical examination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What additional techniques can be used to monitor new lesions?

A

Ultrasound, bone scan, PET scan.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

You MUST use what modality for follow up?

A

The same as you used for baseline, even the same scanner preferable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the basic RECIST paradigm or method?

A

Do a baseline assessment. Select and measure target and non-target lesions. Start treatment. Then do follow up assessments maybe every 3 months. You then measure all the same lesions, as well as recording any new lesions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How do you choose target lesions?

A

They need to be clear cancer lesions, measurable accurately in at least one dimension. Good shape, lymph node can be nice and circular.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How many target lesions do you choose, and max of how many per organ?

A

5, max of 2 in one organ

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How big must each tumour lesion be to measure using method?
CT
Xray
Clinical evaluation (with calipers)
CT for lymph nodes (must be short axis)

A

CT >10mm
Xray 20mm
Calipers 10mm
Lymph node short axis 15mm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How do you create the SLD, the Sum of the Longest Diameters?

A

You add up the longest diameters of non-nodal lesions, and the shortest diameters of the nodal lesions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How do you select non-target lesions?

A

Any other tumour lesion <10mm or lymph nodes 10-14mm. Could be sorts of thickening, things hard to measure on a scan. Never include if there’s a suspicion its not cancerous

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are some examples of non-target lesions?

A

Peritoneal plaques, ascites, pleural effusions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Bone lesions are not target lesions because the way they look may change, not good for measurements. But what can be used to confirm their presence or disappearance?

A

PET scans or Plain films

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Bone lesions may have what that can be measured by CT or MRI?

A

Soft tissue components

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Cystic lesions are not included as lesions usually but what may be?

A

Cystic metastases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What do we do concerning areas of previous radiation?

A

Previously irradiated areas should not be selected as target lesions unless there’s been a demonstrable progression in that lesion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is classed as a complete response?

A

Disappearance of all target and non-target lesions and no new lesions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

In a complete response what happens to lymph nodes?

A

They won’t disappear all together, but they will be <10mm.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

In a partial response what is the target percentage decrease for the SLD of target lesions?

A

> 30% decrease

22
Q

In a partial response what happens to non-target lesions?

A

No progression

23
Q

In Stable disease response what happens?

A

Neither sufficient shrinkage of growth of any target or non-target lesions. and no new lesions.

24
Q

In a progressive disease response, what increase of SLD counts?

A

> 20% SLD increase. OR an absolutely increase of 5mm

25
Q

What other reasons can be classed as a progressive disease response?

A

Progression of non-target lesions, or new lesions that have to be unequivocally new cancer lesions (don’t have to be measurable).

26
Q

What’s a negative about identifying new lesions whilst monitoring (I mean other than it could be a worsening of the cancer)

A

They could be found in anatomical regions no looked at during the baseline.

27
Q

Ultrasound scan new lesions should be confirmed with what?

A

CT or MRI

28
Q

How do cells metastasise?

A

They perform angiogenesis, then EMT to go in the blood stream, they move around and then do an MET when they have the right environment.

29
Q

CELLSEARCH is the gold standard for capturing circulating tumour cells. What method does it use briefly?

A

Immunomagnetic capture. Magnetic beads soaked in epithelial antibody. Blood is passed through beads, so will select for epithelial cells, which should not be present in the blood so are likely metastatic tumour cells. Then stain with other antibodies and visualise and identify.

30
Q

NSCLC advanced patients with more ctCells have what survival?

A

Worse survival

31
Q

The value of ctCells in NSCLC is not great, why?

A

So few of these cells, might find 0-10.

32
Q

But what’s good about ctCells for long term monitoring?

A

Easy to take blood samples. AND when we do capture those cells, they do track with prognosis and provide utility.

33
Q

CELLSEARCH isn’t good at picking up which cells?

A

Those that are a bit more mesenchymal than epithelial

34
Q

Describe a technique that can pick up ctCells that are a bit more mesenchymal than epithelial

A

Using small pores that you let blood cells pass through but big ctCells get stuck in, can then stain them.

35
Q

CELLSEARCH is standardised and scalable which not all technologies are. The other technologies are quite labour intensive and expensive. Name some of the others

A

Isoflux, parsotix, clearbridge, Gilupi, Magsweeper.

36
Q

CtCells Advantages:

A

Invaluable to learn about metastasis. Can characterise cells for biomarkers. Potential to generate mouse models from ctCells.

37
Q

CtCells Disadvantages

A

Expensive. Low number of ctCells. Many technologies. Unlikely to be routine for clinical decision making

38
Q

CtCells have been over taken by what?

A

ctDNA

39
Q

Why do ctDNA VAFs have to be interpreted carefully?

A

There may be subclones in the tumour. A change you find may not be the driver.

40
Q

ctDNA assays have what sensitivity and specificity.

A

High specificity, but low sensitivity.

41
Q

ctDNA samples are really important to what type of patients?

A

Very unwell and frail patients.

42
Q

ctDNA technology is not quite there yet for which applications?

A

Early diagnosis or residual disease detection

43
Q

A quick ctDNA result can prevent what?

A

A patient going on the default of chemo which may be harmful for their mutations.

44
Q

ctDNA has been used to measure LC pateints for EGFR for several weeks, why?

A

Look at exon 19 and check to monitoring if there emergence of any resistance mutations like T790M.

45
Q

ctDNA can detect what type of genetic changes?

A

substitutions, indels, CNAs, Gene rearrangements, TMB and MSI

46
Q

Why are serum tumour markers now cheap as chips?

A

We’ve been capturing these proteins in blood tests for so long now routinely

47
Q

We would love 100% sensitivity and specificity of biomarkers and what other properties?

A

Short half life, easily measurable and reproducible, proportionate to the size of the tumour, cost effective.

48
Q

Name two very common serum marker tests?

A

Prostate Specific Antigen (PSA), and CA125 in ovarian cancer

49
Q

Why is one measurement of serum markers not good enough?

A

An isolated value is no good as it needs to be compared and monitored over time. it’s not informative enough to be diagnostic.

50
Q

What’s better than one marker?

A

A panel

51
Q
A

CancerGen (18 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions